Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01775358 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Safety Study of ALRN-5281 in Healthy Subjects
A Phase 1 study, sponsored by Aileron Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT01775358: Completed Phase 1 study, sponsored by Aileron Therapeutics.
NCT01775358 is a Phase 1 study that has completed, run by Aileron Therapeutics. The registered enrollment target is 33 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (45% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01775358, a Phase 1 study, has completed, sponsored by Aileron Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of a single dose of ALRN-5281 administered by subcutaneous injection to healthy adult volunteers.
Interventions
- DRUG ALRN-5281 0.015 mg/kg
- DRUG ALRN-5281 0.05 mg/kg
- DRUG ALRN-5281 0.15 mg/kg
- DRUG Placebo 0.015 mg/kg
- DRUG Placebo 0.05mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2013-01 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
What the finished NCT01775358 record still lists
NCT01775358 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (45% lower).
The record links to 0 conditions, and to 5 interventions - of which ALRN-5281 0.015 mg/kg is the first listed.
NCT01775358 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01775358 about?
NCT01775358 is a clinical study titled "Phase 1 Safety Study of ALRN-5281 in Healthy Subjects". The primary objective of this study is to evaluate the safety and tolerability of a single dose of ALRN-5281 administered by subcutaneous injection to healthy adult volunteers.
What is the current status of trial NCT01775358?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2013-01. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01775358?
The interventions under investigation include: ALRN-5281 0.015 mg/kg (DRUG), ALRN-5281 0.05 mg/kg (DRUG), ALRN-5281 0.15 mg/kg (DRUG), Placebo 0.015 mg/kg (DRUG), Placebo 0.05mg/kg (DRUG).
Who is sponsoring clinical trial NCT01775358?
This trial is sponsored by Aileron Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01775358's enrollment target sits among peer trials
33 1280th of 2000 higher than 705 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia